Unknown

Dataset Information

0

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.


ABSTRACT: INTRODUCTION:iGlarLixi is a titratable, fixed-ratio combination of insulin glargine (iGlar, 100 units/ml) and the glucagon-like peptide-1 receptor agonist lixisenatide for the treatment of patients with type 2 diabetes. This post hoc analysis of the phase 3 LixiLan-L trial (NCT02058160) investigated baseline characteristics, glycemic control, and safety outcomes in participants who received the study-specified maximum dose (60 units/day) of iGlarLixi or iGlar vs. those who received?

SUBMITTER: Blonde L 

PROVIDER: S-EPMC6822975 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.

Blonde Lawrence L   Bailey Timothy S TS   Chao Jason J   Dex Terry A TA   Frias Juan Pablo JP   Meneghini Luigi F LF   Roberts Michelle M   Aroda Vanita R VR  

Advances in therapy 20190729 9


<h4>Introduction</h4>iGlarLixi is a titratable, fixed-ratio combination of insulin glargine (iGlar, 100 units/ml) and the glucagon-like peptide-1 receptor agonist lixisenatide for the treatment of patients with type 2 diabetes. This post hoc analysis of the phase 3 LixiLan-L trial (NCT02058160) investigated baseline characteristics, glycemic control, and safety outcomes in participants who received the study-specified maximum dose (60 units/day) of iGlarLixi or iGlar vs. those who received < 60  ...[more]

Similar Datasets

| S-EPMC5001145 | biostudies-literature
| S-EPMC6587752 | biostudies-literature
| S-EPMC7003844 | biostudies-literature
| S-EPMC5697595 | biostudies-literature
| S-EPMC5638095 | biostudies-literature
| S-EPMC6221077 | biostudies-literature
| S-EPMC6099242 | biostudies-literature
| S-EPMC9314929 | biostudies-literature
| S-EPMC7245357 | biostudies-literature
| S-EPMC5951239 | biostudies-literature